 THE WOODLANDS, Texas, Dec. 16, 2020 GLOBE NEWSWIRE -- Lexicon Pharmaceuticals, Inc. Nasdaq: LXRX, announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicons patent rights for the compound. LX2931 is a small molecule sphingosine-1-phosphate S1P lyase inhibitor that is currently not in active development at Lexicon. 